Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

BACKGROUND: Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Burtness, Barbara, Bourhis, Jean P, Vermorken, Jan B, Harrington, Kevin J, Cohen, Ezra EW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289298/
https://www.ncbi.nlm.nih.gov/pubmed/25432788
http://dx.doi.org/10.1186/1745-6215-15-469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289298/
https://www.ncbi.nlm.nih.gov/pubmed/25432788
http://dx.doi.org/10.1186/1745-6215-15-469

Ejemplares similares